Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD
Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD
This study will evaluate the safety and efficacy of Jianfei Kangfu Cao in the treatment of
 primary Sjogren's syndrome associated interstitial lung disease.
This study will be a randomized, double-blind, positive control clinical trial with a course
 of 24 weeks.

 1. Random scheme:the DAS for Interactive Web Response System(IWRS) will be used to
 calculate and distribute random numbers and dispensing drugs.

 2. Blind method ：The test process will be in a double-blind state.

 3. Control drug: The lung rehabilitation training will be used as control in this trial.
Inclusion Criteria:

 1. According to the 2012 ACR classification of primary Sjogren's syndrome .

 2. CT confirmed interstitial lung disease;

 3. DLCO≧40%;

 4. Stable treatment for at least 12 weeks;

 5. Patients with good compliance should sign informed consent before the tria.

 Exclusion Criteria:

 1. The patient is using or has used anti pulmonary fibrosis drugs;

 2. Pulmonary infection, tumor and other connective tissue diseases;

 3. Chronic obstructive pulmonary disease, bronchial asthma and tuberculosis;

 4. Patients with severe hypertension, diabetes and heart, liver and renal failure;

 5. Women with reproductive needs;

 6. Idiopathic pulmonary interstitial disease;

 7. The researcher thinks that it is not suitable to participate in this experiment;

 8. Participants in other clinical trials.